A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2016
At a glance
- Drugs NPT 200-11 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Neuropore Therapies
- 18 Feb 2016 Last Checked against ClinicalTrials.gov record.
- 12 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2015 Status changed from planning to recruiting according to a Neuropore media release.